CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. -- Phase 1 ...
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
M uch to the chagrin of investors looking to get rich quickly with a biopharma investment, the drug development cycle is, by ...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...